US Flag logoAn official website of the United States government
NCI CCSG CCDI Supplement Additional Genomic Submission
CCDI
Data Resource:  CCDI
Point of Contact:  
Jeffrey Tyner, PhD,  
Project

About This Dataset
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. This supplement data from the Beat AML program provides Adolescent and Young Adult (AYA) and pediatric tumor specimens not previously released. These data include exome and RNA level characterization as well as analyses of ex vivo drug sensitivity. Collectively, this data can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of leukemia in pediatric and AYA populations.
Core Data Elements
Number of Cases
104
Case Sex
Female (47); Male (57)
Case Age At Diagnosis
0 to 4 years (13); 5 to 9 years (10); 10 to 14 years (11); 15 to 19 years (6); 20 to 24 years (9); 25 to 29 years (8); 30 to 34 years (14); 35 to 39 years (9); Pediatric and Young Adult (<40 years) (24)
Case Race
Unknown (104)
Case Ethnicity
Unknown (104)
Case Disease Diagnosis
Acute megakaryoblastic leukemia (1); Acute monocytic leukemia (4); Acute myeloid leukemia with biallelic mutation of CEBPA (1); Acute myeloid leukemia with mutated NPM1 (3); Acute myeloid leukemia without maturation (1); Acute myeloid leukemia, minimal differentiation (1); Acute myeloid leukemia, NOS (7); Acute myelomonocytic leukemia, NOS (1); Acute promyelocytic leukemia, t(15;17)(q22;q11-12) (2); B lymphoblastic leukemia/lymphoma with hyperdiploidy (4); B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL) (2); B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) (5); B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) (2); B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 (6); B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged (4); B lymphoblastic leukemia/lymphoma, NOS (27); Chronic myeloid leukemia, NOS (20); Mast cell leukemia (1); Precursor T-cell lymphoblastic leukemia (8); Therapy-related myeloid neoplasm (2); Unknown (2)
Case Tumor Site
Blood (37); Bone Marrow (67)
Number of Samples
152
Sample Assay Method
RNA Sequencing (48); Targeted Capture (36); Whole Exome Sequencing (68)
Additional Data Elements
DBGAP STUDY IDENTIFIER
Grant Information
P30CA069533-22S5
OHSU Knight Cancer Institute
Charts
Male (57); Female (47)
57Male